Carole Ho Net Worth

The estimated Net Worth of Carole Ho is at least $13.7 Million dollars as of 20 August 2024. Carole Ho owns over 22,458 units of Denali Therapeutics Inc stock worth over $3,217,375 and over the last 7 years he sold DNLI stock worth over $7,952,002. In addition, he makes $2,489,570 as Chief Medical Officer und Head of Development at Denali Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Carole Ho DNLI stock SEC Form 4 insiders trading

Carole has made over 47 trades of the Denali Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 22,458 units of DNLI stock worth $549,996 on 20 August 2024.

The largest trade he's ever made was exercising 52,906 units of Denali Therapeutics Inc stock on 8 October 2020 worth over $279,344. On average, Carole trades about 6,490 units every 34 days since 2018. As of 20 August 2024 he still owns at least 118,810 units of Denali Therapeutics Inc stock.

You can see the complete history of Carole Ho stock trades at the bottom of the page.

Carole Ho biography

Dr. Carole Ho M.D. serves as Chief Medical Officer, Head of Development of the Company. Dr. Ho currently serves on the board of directors of Beam Therapeutics. Dr. Ho joined Denali from Genentech, where she held various roles of increasing responsibility between 2007 and 2015; from October 2014 to June 2015, Dr. Ho served as Vice President, Non-Oncology Early Clinical Development; from November 2013 to October 2014, Dr. Ho served as Senior Group Medical Director, Early Clinical Development; from April 2011 to November 2013, Dr. Ho served as Group Medical Director, Early Clinical Development; from June 2009 to April 2011, Dr. Ho served as Group Medical Director Global Product Development (Inflammation); and from October 2007 to June 2009, Dr. Ho served as Medical Director, Early Clinical Development. From November 2006 to October 2007, Dr. Ho served as Associate Medical Director at Johnson & Johnson, a health care products company. From June 2002 to November 2006, she was an instructor in the Department of Neurology and Neurological Sciences at Stanford University. Dr. Ho completed a residency in neurology at Partners Neurology Residency of the Massachusetts General and Brigham and Women’s Hospital and was board certified in neurology and psychiatry between 2004 and 2014. Dr. Ho received her M.D. from Cornell University and her B.S. in Biochemical Sciences from Harvard College.

What is the salary of Carole Ho?

As the Chief Medical Officer und Head of Development of Denali Therapeutics Inc, the total compensation of Carole Ho at Denali Therapeutics Inc is $2,489,570. There are 2 executives at Denali Therapeutics Inc getting paid more, with Ryan Watts having the highest compensation of $4,978,610.

How old is Carole Ho?

Carole Ho is 47, he's been the Chief Medical Officer und Head of Development of Denali Therapeutics Inc since 2015. There are 15 older and 4 younger executives at Denali Therapeutics Inc. The oldest executive at Denali Therapeutics Inc is Vicki Sato, 71, who is the Independent Chairman of the Board.

What's Carole Ho's mailing address?

Carole's mailing address filed with the SEC is 151 Oyster Point Blvd, South San Francisco, CA 94080, USA.

Insiders trading at Denali Therapeutics Inc

Over the last 7 years, insiders at Denali Therapeutics Inc have traded over $438,930,443 worth of Denali Therapeutics Inc stock and bought 275,000 units worth $4,950,000 . The most active insiders traders include Llc Fmr, Douglas Kakdl, L.P.Crestlin... und Jay T Flatley. On average, Denali Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $1,606,006. The most recent stock trade was executed by Vicki L Sato on 3 September 2024, trading 3,080 units of DNLI stock currently worth $77,000.

What does Denali Therapeutics Inc do?

denali therapeutics inc. (“denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including alzheimer’s disease, parkinson’s disease, als and others. denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. founding investors include fidelity biosciences, arch venture partners, flagship ventures and the alaska permanent fund (represented by crestline investors).

Complete history of Carole Ho stock trades at Denali Therapeutics Inc, Ngm Biopharmaceuticals Inc und Beam Therapeutics

Denali Therapeutics Inc executives and stock owners

Denali Therapeutics Inc executives and other stock owners filed with the SEC include:

• Ryan Watts,
  President, Chief Executive Officer, Co-Founder, Director
• Steve Krognes,
  Chief Financial Officer, Treasurer
• Carole Ho,
  Chief Medical Officer, Head of Development
• Alexander Schuth,
  Co-Founder, Chief Operating Officer, Secretary
• Dr. Ryan J. Watts Ph.D.,
  Co-Founder, Pres, CEO & Director
• Steve Edward Krognes,
  CFO & Treasurer
• Dr. Carole Ho,
  Chief Medical Officer & Head of Devel.
• Dr. Alexander O. Schuth M.D.,
  Co-Founder, COO & Sec.
• Dr. Carole Ho M.D.,
  Chief Medical Officer & Head of Devel.
• Vicki Sato,
  Independent Chairman of the Board
• Marc Tessier-Lavignec,
  Independent Director
• Peter Klein,
  Independent Director
• David Schenkein,
  Independent Director
• Jay Flatley,
  Independent Director
• Douglas Cole,
  Independent Director
• Robert Nelsen,
  Independent Director
• Jennifer Cook,
  Independent Director
• Dr. Marc Tessier-Lavigne Ph.D.,
  Co-Founder, Chairman of Scientific Advisory Board & Independent Director
• Dr. Marc Tessier-Lavigne,
  Co-Founder, Chairman of Scientific Advisory Board & Independent Director
• Chris Walsh,
  Associate Gen. Counsel
• Dr. Laura Hansen,
  VP of Investor Relations
• Joe Lewcock,
  Chief Scientific Officer
• Dr. Dana Andersen,
  Chief Technical and Manufacturing Officer
• Tyler M. Nielsen,
  VP of Corp. Fin.
• Douglas Kakdl, L.P.Neuro Li...,
  
• Ventures Fund V, L.P.Afeyan...,
  
• Marc Tessier Lavigne,
  Director
• Ltd Fil,
  
• Llc Fmr,
  
• Venture Fund Viii, L.P.Arch...,
  
• Douglas K Neuro Line Partne...,
  
• Douglas Kakdl, L.P.Crestlin...,
  
• Nancy Thornberry,
  Director
• Erik Harris,
  Director